The microbiome industry is on the cusp of a turning point.
Seres Therapeutics (MCRB), one of the biggest companies in the field, is set to unveil results from a pivotal clinical trial for its potential fecal matter-derived drug this summer. Two other major players, Rebiotix and Finch Therapeutics, could announce trial results for similar therapies around the same time.
The late-stage data will thrust the microbiome industry into the spotlight for the first time since a high-profile clinical failure in 2016 threw a shadow over the field. Strong results could renew some of the initial interest — and investments — that helped the field get off the ground. Or it could dry up the business community’s interest entirely.
About the Author Reprints
